<DOC>
	<DOCNO>NCT00116597</DOCNO>
	<brief_summary>The purpose study ass intranodal immunotherapy locally advance metastatic melanoma patient ( American Joint Committee Cancer [ AJCC ] stag IIb IV ) . For , investigator capitalize previous melanoma clinical trial ( publish Zajac P et al Human Gene Ther 2003 ) take advantage proprietary recombinant vaccinia virus ( replication inactivate ) express 5 minigenes : 3 melanoma associate antigens 2 costimulatory molecule . Immunization recombinant vaccinia virus follow 3 boost soluble , synthetic melanoma associate antigen . The patient immunize intranodally ( groin lymph node ) ultrasonographic guidance outpatient clinic . The protocol foresee 2 cycle immunotherapy alternate week last 15 week .</brief_summary>
	<brief_title>Active Specific Intranodal Immunotherapy Recombinant Vaccinia Virus Locally Advanced Metastatic Melanoma</brief_title>
	<detailed_description>The investigator conduct phase I/II clinical trial base intradermal administration stage III/IV melanoma patient recombinant vaccinia virus encode tumor associate antigen costimulatory epitope prim immune response , follow boost correspond synthetic peptide ( Zajac P et al Human Gene Ther 2003 ) . Specific cytotoxic T cell could induce majority patient follow priming , sustain responsiveness could maintain peptide boost long term basis . Emerging evidence support notion expansion specific T cell require traffic antigen present cell load specific determinant lymphatic node , induce , among others , pro-inflammatory stimulus . Therefore , adopt intranodal injection immunogenic formulation . As former melanoma active specific immunotherapy trial , GM-CSF use support cytokine . The epitope consider express , either , 90 % melanomas Western country ; namely , immunize Mart-1/Melan-A epitope 27-35 , Gp-100 epitope 280-288 tyrosinase epitope 1-9 . As consequence , HLA-A2 positivity mandatory inclusion trial . The 2 costimulatory molecule express cell infect replication-incompetent recombinant vaccinia virus B7.1 ( CD80 ) B7.2 ( CD86 ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients older 18 year Histologically proven melanoma AJCC stage IIb IV Resected , recurrent disseminate disease HLAA2.1 MHC phenotype Karnofsky performance status equal high 70 % Patients young 18 year Pregnancy inability perform anticonception MHC phenotype HLAA2.1 Other concurrent malignant disease Estimated life expectancy le 6 month Allergic skin disease , include eczema , psoriasis neurodermitis Fever active infection respiratory system Concurrent severe cardiac pulmonary disease ( New York Heart Association [ NYHA ] III IV ) Significant impairment liver kidney function ( bilirubin &gt; 30umol/l , GOT &gt; 2.5xN , GPT &gt; 2.5xN , alkaline phosphatase &gt; 2.5xN , creatinine &gt; 1.5xN adapted age ) Impairment immune system ( leucocyte count &lt; 3000/mm3 granulocyte count &lt; 1500/mm3 ) Concurrent immunosuppressive therapy Preexisting severe anemia ( hemoglobin low 80 g/l ) Preexisting thrombocytopenia ( platelet count low 75,000/ul ) Ongoing chemotherapy chemotherapy complete less 6 week enrollment trial Any medical psychiatric condition , opinion treat physician principal investigator , would unacceptably reduce safety propose treatment , would impair delivery treatment , would preclude obtain voluntary informed consent Patients receive concurrent investigational treatment , concurrent treatment cancer Patients avoid close contact child le 3 year age immunocompromised household member</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Active Specific Immunotherapy</keyword>
	<keyword>Intranodal</keyword>
	<keyword>Cancer</keyword>
	<keyword>Melanoma stag IIb IV</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Recombinant Vaccinia virus</keyword>
	<keyword>HLA-A2</keyword>
	<keyword>Mart-1/Melan-A , Gp-100 , tyrosinase</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Phase I/II</keyword>
</DOC>